Pathologic complete response (pCR) to preoperative sequential doxorubicin/cyclophosphamide (AC) and taxane (AC-T) or AC followed by paclitaxel and trastuzumab (AC-TH) in stage II-III HER2-positive breast cancer

被引：0
|
作者：
Chumsri, S.
Jeter, S. C.
Jacobs, L. K.
Lange, J. R.
Davidson, N. E.
Emens, L. A.
Fetting, J. H.
Gabrielson, E.
Zhang, Z.
Stearns, V.
机构：
[1] Univ Maryland, Med Ctr, Baltimore, MD 21201 USA
[2] Kimmel Canc Ctr Johns Hopkins, Baltimore, MD USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.11521
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
11521
引用
收藏
页数：1
相关论文
共 50 条
  • [11] BACH: A randomized phase II trial of doxorubicin-cyclophosphamide (AC) versus pegylated liposomal doxorubicin (PLD)-cyclophosphamide-trastuzumab (CCH) followed by paclitaxel-trastuzumab (TH) as adjuvant therapy for HER2-positive breast cancer (BC)-Cardiac safety analysis.
    Rayson, D.
    Suter, T.
    van der Vegt, S.
    Lluch, A.
    Van Den Bosch, J.
    Lopez-Vivanco, G.
    Van Gent, A. M.
    Wildiers, H.
    Provencher, L.
    Richel, D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [12] Cardiac safety analysis of the first stage of NSABP B-31, a randomized trial comparing the safety and efficacy of doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) to that of AC followed by paclitaxel plus trastuzumab (TH) in patients (pts) with operable, node-positive (N+), HER-2 overexpressing breast cancer (HER2+BC)
    Geyer, C.
    Bryant, J.
    Romond, E.
    Tan-Chiu, E.
    Ewer, M.
    Keefe, D.
    Shannon, R.
    Yothers, G.
    Wolmark, N.
    [J]. EJC SUPPLEMENTS, 2004, 2 (03): : 141 - 141
  • [13] Phase 2 Study of Neoadjuvant Treatment with Cellular Redox Modulator NOV-002 in Combination with Doxorubicin and Cyclophosphamide Followed by Docetaxel (AC→T) in Patients with Stage II-III HER-2 (-) Breast Cancer
    Montero, A. J.
    Diaz, C. M.
    Slingerland, J.
    Pegram, M.
    Hurley, J.
    Welsh, C. F.
    Avisar, E.
    Seo, P.
    Vogel, C. L.
    Garrett-Mayer, E.
    Hermann, V.
    Baker, M. K.
    Silva, O.
    Koniaris, L.
    Rodgers, S.
    Schuhwerk, K.
    Pazoles, C. J.
    Moffat, F.
    Cole, D. J.
    Gluck, S.
    [J]. CANCER RESEARCH, 2010, 70
  • [14] Pathologic complete response (pCR) following weekly (wkly) paclitaxel (cremophor or albumin-bound) and carboplatin (TC) ± trastuzumab (H), ± bevacizumab (B) in patients (pts) with doxorubicin/cyclophosphamide-resistant (AC-Res) and AC-sensitive (AC-S) large and inflammatory breast cancer
    Mehta, R. S.
    Schubbert, T.
    Kong, K.
    Hsiang, D.
    Butler, J.
    Baick, C.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [15] Doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) with or without trastuzumab (H) as adjuvant therapy for patients with HER2-positive operable breast cancer (BC): combined analysis of NSABP B-31 and NCCTG N9831
    Romond, E. H.
    Perez, E. A.
    Bryant, J.
    Suman, V.
    Geyer, C. E.
    Davidson, N.
    Paik, S.
    Martino, S.
    Kaufman, P.
    Wolmark, N.
    [J]. EJC SUPPLEMENTS, 2005, 3 (02): : 73 - 73
  • [16] Economic evaluation of adjuvant therapy in node-positive breast cancer: a comparison between doxorubicin & cyclophosphamide plus paclitaxel (AC-T) and cyclophosphamide, epirubicin and 5-fluorouracil (CEF).
    Rao, SC
    Verma, S
    Dahrouge, S
    Mohindra, R
    Hopkins, S
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2001, 69 (03) : 252 - 252
  • [17] Mature cardiac safety results of dose-dense (DD) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) with trastuzumab (H) in HER2/neu overexpressed/amplified breast cancer (BCA).
    Dang, C.
    Smith, K.
    Fornier, M.
    Sugarman, S.
    Troso, T.
    Lake, D.
    D'Andrea, G.
    Seidman, A.
    Sklarin, N.
    George, R.
    Dickler, M.
    Currie, V
    Gilewski, T.
    Moynahan, M. E.
    Drullinsky, P.
    Poznak, C.
    Robson, M.
    Wasserheit, C.
    Mills, N.
    Steingart, R.
    Norton, L.
    Hudis, C.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S114 - S115
  • [18] Updated cardiac safety results of dose-dense (DD) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) with trastuzumab (H) in HER2/neu overexpressed/amplified breast cancer (BCA).
    Dang, C.
    Smith, K.
    Fornier, M.
    Sugarman, S.
    Troso-Sandoval, T.
    Lake, D.
    D'Andrea, G.
    Seidman, A.
    Sklarin, N.
    Norton, L.
    Hudis, C.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 23S - 23S
  • [19] Preliminary cardiac safety results of dose-dense (DD) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) with trastuzumab (H) in HER2/neu overexpressed/amplified breast cancer (BCA)
    Dang, C
    Smith, K
    Lake, D
    Fornier, M
    D'Andrea, G
    Seidman, A
    Sklarin, N
    Troso-Sandoval, T
    Sugarman, S
    Gilewski, T
    Robson, M
    Drullinsky, P
    Moynahan, M
    George, R
    VanPoznak, C
    Panageas, K
    Smith, M
    Norton, L
    Hudis, C
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S98 - S98
  • [20] NSABP FB-7: A phase II randomized trial evaluating neoadjuvant therapy with weekly paclitaxel (P) plus neratinib (N) or trastuzumab (T) or neratinib and trastuzumab (N plus T) followed by doxorubicin and cyclophosphamide (AC) with postoperative T in women with locally advanced HER2-positive breast cancer
    Jacobs, S. A.
    Robidoux, A.
    Garcia, J. M. P.
    Abraham, J.
    La Verde, N.
    Orcutt, J. M.
    Cazzaniga, M. E.
    Calvo, L.
    Aguirre, E.
    Buyse, M.
    Pogue-Geile, K. L.
    Srinivasan, A.
    Song, N.
    Balousek, A. D.
    Wolmark, N.
    [J]. CANCER RESEARCH, 2016, 76
12345